~~<i id='424A5DBA5F'><strike id='424A5DBA5F'><tt id='424A5DBA5F'><pre id='424A5DBA5F'></pre></tt></strike></i>~~

Home» comprehensive» focus

focus

author：knowledge 2025-10-06 06:57:30 Page View：99547

Hiram Secrist (left), who has Duchenne muscular dystrophy, with his mother, Kristen Secrist (center), and his grandmother, Terrie Jordan. Courtesy Secrist family

In mid-July, Kristen Secrist hopped on a call with her 5-year-old son’s doctor, who had urgent news: The first gene therapy had been approved for Duchenne muscular dystrophy. Her son, Hiram, would be a perfect candidate — if, she added, they could get him dosed in time.

The treatment was approved only for 4- and 5-year-olds. Hiram turned 6 in three weeks.

“Oh, crap,” Secrist said to herself.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Blood tests recalled over risk of missed heart attack diagnosis
Next article： Moonlake's readout produced a cash windfall. Risks remain

explore

Hepatitis C has a cure — but many Americans still lack access to it

AdobeIn2005,NickVoyleswasdiagnosedwithhepatitisCafterbeingreleasedfromfiveyearsofincarceration.Anurs

What PEPFAR has meant on the ground in Ukraine

JonathanErnst/APInUkraine,alittlebitofgoodnewscangoalongway,andthelifesavingworkbeingdoneasaresultof

George Santos makes 1st court appearance after pleading not guilty to 13 counts

1:57GeorgeSantosarrivesatfederalcourtJune30,2023,inCentralIslip,N.Y.JohnMinchillo/APRep.GeorgeSantos

Eli Lilly to acquire Versanis in heated race for weight loss drugs

DarronCummings/APEliLillysaidFridayitwillacquireVersanisBio,aprivatecompanydevelopinganobesitydrugth